MC1 |CAS 1018480-89-1|DC Chemicals

Cas No.:	1018480-89-1
Chemical Name:	MC1 Precursor
Synonyms:	6-Methoxy-2-[4-(methylsulfonyl)phenyl]-N-(2- thienylmethyl)-4-pyrimidinamine
SMILES:	O=S(C1=CC=C(C2=NC(OC)=CC(NCC3=CC=CS3)=N2)C=C1)(C)=O
Formula:	C₁₇H₁₇N₃O₃S₂
M.Wt:	375.47
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC67437	PI-2620 precursor	PI-2620 precursor is the precursor of PI2620. 18F-PI-2620 is a PET tracer with high binding affinity for aggregated tau, a key pathologic feature of Alzheimer disease (AD) and other neurodegenerative disorders.
DC60818	mono-Boc-Br MK-6240 Precursor	mono-Boc-Br MK-6240 Precursor is the precusor of MK-6240.. (18)F]-MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs .
DC67285	DOTA-Octreotide
DC67284	NOTA-NOC
DC60791	Cholestify Precursor	Precursor of Cholestify,18F-Cholestify, which binds cytochrome P450 46A1, detected cholesterol breakdown in the mammalian brain. CYP46A1 converts cholesterol to 24-hydroxycholesterol, a form easily eliminated from the brain.
DC60790	DesMEM AZD4694	DesMEM AZD4694（AZD4694 Precursor 1）is the precursor of [18F] AZD4694 for the synthesis of [18F] AZD4694, an amyloid-β imaging ligand with high affinity for amyloid-β plaques.
DC66469	DOTA-NOC	DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging.
DC66468	NOTA-octreotide	NOTA-octreotide is a ligand for making [18F]AlF-NOTA-octreotide, which is a PET/CT imaging agent for somatostatin receptor imaging in neuroendocrine tumor patients
DC66467	F-PSMA 1007
DC66465	Pentanedioate	Pentanedioate is a valuable starting material for the synthesis of PSMA inhibitors due to its flexible structure and functional groups that mimic natural PSMA ligands. By leveraging its chemical properties, researchers can develop potent and selective PSMA-targeting agents for diagnostic imaging, targeted therapy, and theranostic applications in prostate cancer and other PSMA-expressing malignancies. Its role in drug discovery highlights the importance of simple organic molecules in the development of advanced cancer therapies.